{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nSNORA70E, a box H/ACA small nucleolar RNA, is significantly elevated in ovarian cancer tissues and correlates with an unfavorable prognosis. Its overexpression promotes enhanced cell proliferation, invasion, and migration in vitro, as well as increased tumor growth in vivo, indicating a key role in ovarian tumorigenesis."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "Mechanistically, SNORA70E exerts its oncogenic effects through dual regulatory pathways. First, by binding with the pyrimidine synthase Dyskerin Pseudouridine Synthase 1 (DKC1), SNORA70E facilitates pseudouridylation modification of RAS-Related Protein 1B (RAP1B) mRNA, resulting in elevated RAP1B protein levels and activation of downstream signaling molecules including β-catenin, PI3K, AKT1, mTOR, and MMP9. Second, RNA sequencing revealed that SNORA70E influences the alternative splicing of PARP-1 binding protein (PARPBP), causing the skipping of the 4th exon in PARPBP-88 and the formation of a novel transcript, PARPBP-15, which further drives cell invasion, migration, and proliferation."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "Finally, the study demonstrated that antisense oligonucleotide (ASO)–mediated silencing of SNORA70E significantly inhibited ovarian cancer cell proliferation, migration, and invasion in vitro, as well as tumorigenicity in vivo. These findings underline the potential of SNORA70E not only as a biomarker for ovarian cancer prognosis but also as a promising therapeutic target."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Shuo Chen, Qian-Hui Li, Xi Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "SNORA70E promotes the occurrence and development of ovarian cancer through pseudouridylation modification of RAP1B and alternative splicing of PARPBP."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Mol Med (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/jcmm.17540"}], "href": "https://doi.org/10.1111/jcmm.17540"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "36056690"}], "href": "https://pubmed.ncbi.nlm.nih.gov/36056690"}]}]}]}